Survival from coma induced by an intentional 36-g overdose of extended-release quetiapine.

Quetiapine is a second-generation antipsychotic drug approved for the treatment of bipolar disorders and schizophrenia. Acute quetiapine overdose is rare, and quetiapine has long been thought to be safer than other antipsychotics. Nevertheless, as reported in the literature, the severity of the effect of quetiapine overdose has not been associated with a high serum concentration of the drug or with the reported ingested dose. In this article, we report a case of survival from coma induced by a massive extended-release (XR) quetiapine ingestion at a dose greater than reported in some previous fatal cases. A 34-year-old woman with chronic schizophrenia ingested 36 g of quetiapine fumarate XR for attempted suicide. She was initially lethargic, but her clinical conditions rapidly deteriorated and she collapsed unconscious. The woman was taken to the nearest hospital, where the medical emergency team found her in deep coma with response only to deep painful stimuli (Glasgow Coma Scale 9). An endotracheal tube was inserted for airway protection, and the patient was transferred to a critical care area for ventilatory support and maintenance of hydration status and electrolytic balance. Spontaneous breathing was restored in approximately 36 hours, and a few days later, she was discharged without reporting clinical complications. This is the first case of coma induced by an intentional 36-g overdose of quetiapine XR. Given the widespread use of quetiapine and the lack of information about its toxicity in overdose, this case report reinforces the importance of closely monitoring patients taking quetiapine and helps to better define the safety of this drug.

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.

According to European recommendations, the Italian Medicines Agency (AIFA) required close monitoring of the safety of the MF59-adjuvanted H1N1v vaccine, which was the only vaccine available in Italy for prophylaxis of the A/H1N1 (2009) pandemic influenza. From October 2009 to June 2010, the Italian Pharmacovigilance Adverse Event (AE) Spontaneous Reporting System [Rete Nazionale Farmacovigilanza] (RNF) received 1330 reports of AEs temporally related with the pandemic influenza vaccination out of a total of 924,057 doses administered. Among these, 1,162 (87.37%) AE reports were classified 'non serious', 91 (6.84%) 'serious', 3 (0.23%) had a fatal outcome and 74 (5.56%) did not include the degree of seriousness. Among the serious AE reports, some unexpected AEs emerged. Even though some typical vaccine safety issues which emerged should be further explored, such as vaccination in pregnancy, the analysis of all AE reports sent to RNF shows that the vaccine has a well-tolerated safety profile which resembles that of the already available seasonal influenza vaccines. This contrasts with the widespread public concern about its safety, which has been one of the major causes of the low vaccination rate observed in Italy, as well as in other countries.

[Hospital consumption of antibiotics at the Policlinico Hospital of the Second University of Naples: results of retrospective data collection]. / Monitoraggio delle prescrizioni di antibiotici nei reparti dell'A.O.U. Policlinico Seconda Università di Napoli attraverso l'analisi retrospettiva dei consumi.

In the therapeutic field, analysis of antibiotics consumption and use is of great importance: it is considered a necessary prerequisite for initiating measures to rationalize the use of antibiotics, but also to limit bacterial resistance. In this light, we conducted an observational study on antibiotics consumption at the Policlinico University Hospital in Naples to evaluate the prescription of antibiotics in the hospital's four main divisions. We used the Defined Daily Dose (DDD) as a measure of antibiotics consumption, and collected data retrospectively from 2006 to 2007. Our findings clearly show a 23.3% increase in antibiotics consumption in 2007 vs 2006. The classes of antibiotics experiencing the greatest percentage increases were penicillins and other beta-lactams, quinolones and glycopeptides. In particular, among other beta-lactams (J01D) in 2007 was the consumption of third-generation cephalosporins and carbapenems. The surgical division showed the largest increase in use of antibiotics, while in intensive care we found a reduction. Our data suggest consumption data should be compared with information on prescriptions and costs so as to monitor more closely the consumption of antibiotics and thus rationalize their use with a view to reducing the phenomenon of bacterial resistance. Finally, it would be useful to launch a training program for the proper use of antibiotics in our University Hospital.